Product

Relapsed Glioblastoma

1 clinical trial

2 indications

Indication

Relapsed Cancer

Indication

Glioblastoma IDH Wildtype

Clinical trial

Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.

Status: Not yet recruiting, Estimated PCD: 2025-07-01